• Go 6983: pan-PKC Inhibitor for PKC Signaling Pathway Researc

  2026-05-11

  Go 6983 delivers nanomolar inhibition of key PKC isoforms, empowering high-precision PKC signaling pathway research from cancer progression to early embryonic lineage commitment. This guide translates cutting-edge findings and best-practice workflows into actionable protocols, troubleshooting insights, and strategic advantages for scientists leveraging APExBIO’s Go 6983.

• DAPT (GSI-IX): A Potent γ-Secretase Inhibitor for Notch & AP

  2026-05-11

  DAPT (GSI-IX) is a selective, orally bioavailable γ-secretase inhibitor used to block Notch signaling and amyloid precursor protein processing in research. Its validated potency and specificity make it a standard tool in Alzheimer's disease, cancer, and autoimmune disorder studies. This article summarizes its mechanism, applications, and protocol parameters with direct citation of primary evidence.

• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole: Workflow & In

  2026-05-10

  5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) empowers researchers to dissect transcriptional elongation and cyclin-dependent kinase signaling in precise, reproducible workflows. Its high potency and validated specificity make it a cornerstone for advanced studies in gene regulation, antiviral assays, and cell fate engineering.

• Bradford Protein Assay Kit: Protocol Parameters and Best Pra

  2026-05-09

  The Bradford Protein Assay Kit provides a rapid, sensitive biochemical protein assay for quantifying protein concentrations in solution, ideal for molecular biology and biochemical research workflows. It is most effective for samples free of interfering substances and unsuitable for absolute quantification of atypical proteins or detergent-rich lysates.

• Optimizing Cytotoxicity Assays with Mianserin Hydrochloride

  2026-05-08

  This article addresses real-world challenges in cell-based assays, emphasizing how Mianserin Hydrochloride (SKU A1796) from APExBIO offers reproducible, data-backed solutions for researchers studying cell viability and serotonin receptor modulation. Drawing on clinical and mechanistic evidence, it guides laboratory scientists through best practices, protocol parameters, and vendor selection for antidepressant research compounds.

• Enhancing Arthritis and Inflammation Assays with T-5224 (C-F

  2026-05-08

  This article guides biomedical researchers through common assay challenges in inflammation and arthritis research, demonstrating how T-5224 (C-Fos/AP-1 inhibitor, SKU B4664) addresses reproducibility, selectivity, and workflow optimization. Evidence-backed scenario Q&As highlight its performance advantages and best practices for reliable experimental outcomes.

• Perphenazine: Dopamine D2 Antagonist Workflows in Research

  2026-05-07

  Perphenazine, a dopamine D2 receptor antagonist, stands out for its multi-receptor pharmacology, enabling reproducible neuropharmacology and host-pathogen interaction studies. This article translates bench evidence and new host-directed therapy findings into actionable workflows and troubleshooting tips for modern research labs.

• Bazedoxifene’s Antimalarial Activity: Inhibiting Hemozoin Fo

  2026-05-07

  This study demonstrates that bazedoxifene, a third-generation selective estrogen receptor modulator, exhibits potent antimalarial effects by inhibiting hemozoin formation in Plasmodium falciparum. The findings highlight bazedoxifene’s potential for drug repurposing beyond osteoporosis, with implications for combating drug-resistant malaria.

• Ferritin-Based Hybrid Vaccine: Dual Antigen Strategy for Inf

  2026-05-06

  This study introduces a ferritin-based hybrid protein particle vaccine that co-displays influenza A M2e and SARS-CoV-2 S-protein tandem epitopes, enabling robust and multivalent immune responses. The approach leverages E. coli expression and ferritin self-assembly, demonstrating enhanced antibody titers and viral inhibition—offering a promising platform for efficient combination vaccine development.

• GSTA1 Drives Glutathione Loss in α-Amanitin Liver Toxicity

  2026-05-06

  This study uncovers a paradoxical role for GSTA1 in α-amanitin-induced hepatotoxicity, revealing that GSTA1 upregulation accelerates glutathione depletion and exacerbates oxidative stress. The findings reposition GSTA1 from a classical hepatic detoxifier to a key pathogenic driver, highlighting new opportunities for targeting glutathione metabolism in acute liver injury.

• Deferiprone in Cancer and Metabolism: Protocols and Use Case

  2026-05-05

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is a versatile iron chelator that empowers precise control of iron-dependent signaling in cancer biology and enterocyte metabolism studies. This article delivers actionable workflows, troubleshooting strategies, and evidence-backed insights for researchers leveraging Deferiprone from APExBIO to dissect iron’s role in apoptosis, cytoprotection, and metabolic reprogramming.

• Mechanistic Insights into Gepotidacin Action on S. aureus Gy

  2026-05-05

  This study elucidates the structural and mechanistic basis for Gepotidacin’s inhibition of Staphylococcus aureus DNA gyrase, highlighting its unique mode of inducing single-stranded DNA breaks and its robust activity against fluoroquinolone-resistant bacteria. These findings inform antibacterial research on overcoming resistance and designing next-generation topoisomerase inhibitors.

• 5-HT3 Antagonists Inhibit Renal OCT2 and MATE1: In Vitro Ins

  2026-05-04

  This study demonstrates that antiemetic 5-HT3 receptor antagonists, including Tropisetron Hydrochloride, inhibit renal cation transporters OCT2 and MATE1 in vitro. These findings provide mechanistic insight into potential drug-drug interactions affecting renal drug secretion, with implications for neuroscience and pharmacology research.

• BRD4 Inhibition Enhances Ferroptosis via ROS and FSP1 Downre

  2026-05-04

  This study demonstrates that BRD4 inhibition, using small molecules such as I-BET-762, broadly promotes erastin-induced ferroptosis in various cancer cell lines by increasing ROS and downregulating FSP1. The findings clarify BRD4's role in ferroptosis and suggest BET inhibitors as potential combinatorial partners for ferroptosis-inducing therapies in cancer research.

• Systematic Review: Tamsulosin Increases Ureteral Stone Expul

  2026-05-03

  This meta-analysis synthesizes data from 49 studies to clarify the efficacy and safety of Tamsulosin for symptomatic ureteral stone expulsion. The findings demonstrate a significant improvement in stone clearance rates and reduced expulsion time, with no increase in adverse events, supporting the use of Tamsulosin as an effective α1A-adrenergic receptor antagonist in urological research.

15579 records 1/1039 page Next 12345 下5页 Last page